Paris-based Ennov, a software provider for regulated life sciences companies, received a growth investment from Bregal Sagemount and Ardian.

The company serves pharmaceutical, biotechnology and medical device customers operating in compliance-heavy healthcare markets.

Ennov’s software is used to manage regulatory information, quality processes, clinical documentation and pharmacovigilance workflows.

Those functions sit across drug and device development, approval and post-market monitoring, where customers must maintain controlled records and auditable processes.

The transaction gives Bregal Sagemount and Ardian a vertical software platform focused on life sciences compliance.

Bregal Sagemount has raised more than $11 billion of capital and made more than 90 investments across software, healthcare IT, financial technology and business services.

Additional details on valuation, debt financing, seller participation and outside advisers were not provided in the deal record.